甲氨蝶呤联合羟氯喹与甲氨蝶呤单药治疗早期类风湿关节炎患者的疗效对比
该对照队列研究纳入325例早期RA患者,比较甲氨蝶呤联合羟氯喹(CTG)与甲氨蝶呤单药(MTG)的疗效。6个月时CTG组DAS28-CRP改善更大(Δ=0.38),良好EULAR应答比例更高(Δ=15%);12个月时两组差异无统计学显著。
要点
- 12个月时两组DAS28-CRP改善及EULAR应答差异均无统计学显著。
核心结论
- 与间接比较综述数据相反,MTX-HCQ联合治疗在6个月时似乎比MTX单药略更有效;12个月时两种策略间未观察到显著差异,可能归因于达标治疗努力。
研究设计与样本
- 来自Sint Maartenskliniek和Radboudumc Nijmegen的对照队列研究,纳入2010年4月至2015年10月期间开始MTX联合或不联合HCQ的RA患者,共325例。
- 主要结局为6个月时组间DAS28-CRP变化(ΔDAS28-CRP),次要结局包括12个月时ΔDAS28-CRP、6个月和12个月时EULAR应答及治疗强化;采用回归模型校正混杂。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the added value of MTX-HCQ combination therapy (CTG) in early RA in a controlled cohort study. MTX monotherapy (MTG) is recommended as (part of) first choice treatment but no head-to-head comparisons are available comparing MTX-HCQ CTG with MTG. METHODS: RA patients from the Sint Maartenskliniek and Radboudumc Nijmegen who started MTX with or without concomitant HCQ from April 2010 to October 2015 were included. The primary outcome was the between-group ΔDAS28-CRP at 6 months, and secondary outcomes were ΔDAS28-CRP at 12 months, EULAR response at 6 and 12 months, and treatment intensification. Regression modelling was used to correct for confounding. RESULTS: We included 325 patients, with only small between-group differences at baseline. The DAS28-CRP improvement at 6 months was larger in the CTG (Δ = 0.38 (CI: 0.01, 0.76)), and the difference between groups in DAS28-CRP improvement was smaller at 12 months (Δ = 0.22 points (CI:-0.19, -0.62)). At 6 months, a higher percentage of patients had a good EULAR response in the CTG (Δ = 15% (CI: 2.7%, 27%)). This difference was reduced at 12 months (Δ = 6% (CI -6.4%, 19%)). Treatment intensification with conventional synthetic DMARDs was more likely in the MTG (Δ = 31% (CI: -43%, 19%)). The proportion of patients starting biologic DMARD treatment during the observation period was comparable (Δ = 2% (CI: -8%, 12%)). DISCUSSION: In contrast to indirect comparison review data, MTX-HCQ seems somewhat more effective after 6 months than MTX monotherapy in early RA patients. After 12 months, we observed no significant differences between the two strategies, probably due to treat-to-target efforts.
引用
- Schapink L, van den Ende CHM, Gevers LAHA, et al. The effects of methotrexate and hydroxychloroquine combination therapy vs methotrexate monotherapy in early rheumatoid arthritis patients. Rheumatology (Oxford). 2019. PMID: 30189019. doi:10.1093/rheumatology/key275
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。